Cel-Sci encouraged by data from study of Multikine for cancer

By Lisa Kerner

Erie, Pa., March 8 - Cel-Sci Corp. said that recently analyzed follow-up data from its key phase 2 clinical trial with the cancer drug Multikine indicates that the drug had a substantial effect on the survival of the patients treated with it.

The company released the information in a letter to its shareholders.

According to the letter, the long-term follow-up study of the head and neck cancer patients who received Multikine over three years ago showed an in survival rate and the local regional control of their tumors.

Cel-Sci said it plans to publish detailed results in a scientific journal.

The company also plans a phase 3 clinical trial, with the endpoints being local regional control of the tumor and survival. While Canadian regulators have cleared the study, Cel-Sci still needs approval from the Food and Drug Administration.

The letter also referenced Cel-Sci's agreement with the National Institute for Allergy and Infectious Diseases regarding testing of CEL-1000 drug against the avian flu virus in animal models. The company has since added more testing of Cel-Sci against the avian flu virus, in addition to testing being done by the institute.

Cel-Sci, a Vienna, Va.-based biotechnology company, develops drugs and vaccines for the treatment of cancer and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.